FDA-approved drug repurposing screen identifies inhibitors of SARS-CoV-2 pseudovirus entry
We identified four novel FDA-approved candidate drugs for anti-SARS-CoV-2 combination therapy. Our findings contribute to the growing body of evidence supporting drug repurposing as a viable strategy for rapidly developing COVID-19 treatments.
Authors
- Raghda E. Eldesouki (ORCID: https://orcid.org/0000-0002-8860-3484)
- Maged M. Harraz (ORCID: https://orcid.org/0000-0003-4353-4216)
- Shruthi Shanmukha (ORCID: https://orcid.org/0000-0001-5659-2250)
- Manisha Singh (ORCID: https://orcid.org/0000-0002-0466-8986)
Institutions
- Suez Canal University (EG)
- University of Maryland, Baltimore (US)
- Johns Hopkins University (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.3389/fphar.2025.1537912
- Citations
- 2
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 2.79
Funders
- Maryland Stem Cell Research Fund